Literature DB >> 10508047

Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactam.

M Backo1, E Gaenger, A Burkart, Y L Chai, A S Bayer.   

Abstract

We evaluated several 3-day antimicrobial regimens in the treatment of experimental endocarditis caused by an oxacillin-resistant Staphylococcus aureus strain exhibiting intermediate susceptibility in vitro to vancomycin (VISA). Neither vancomycin alone nor trovafloxacin exhibited in vivo efficacy; addition of amikacin to vancomycin yielded a modest in vivo effect. In contrast, the combination of ampicillin and sulbactam was highly effective in vivo, causing a mean decrease in VISA vegetation densities of >5 log(10) CFU/g versus those of untreated controls.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10508047      PMCID： PMC89523          DOI： 10.1128/AAC.43.10.2565

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

Review 1.  Valve site-specific pathogenetic differences between right-sided and left-sided bacterial endocarditis.

Authors:  A S Bayer; D C Norman
Journal:  Chest       Date:  1990-07       Impact factor: 9.410

2.  Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin.

Authors:  R L Patron; M W Climo; B P Goldstein; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

3.  Chemoprophylactic efficacy against experimental endocarditis caused by beta-lactamase-producing, aminoglycoside-resistant enterococci is associated with prolonged serum inhibitory activity.

Authors:  A S Bayer; J Tu
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

4.  Studies on antibiotic synergism against enterococci. I. Bacteriologic studies.

Authors:  R C Moellering; C Wennersten; A N Weinberg
Journal:  J Lab Clin Med       Date:  1971-05

5.  Beta-Lactam-beta-lactamase-inhibitor combinations are active in experimental endocarditis caused by beta-lactamase-producing oxacillin-resistant staphylococci.

Authors:  L Hirano; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

6.  Ampicillin-sulbactam is effective in prevention and therapy of experimental endocarditis caused by beta-lactamase-producing coagulase-negative staphylococci.

Authors:  M C Ramos; M Ing; E Kim; M D Witt; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

7.  Comparative pharmacokinetics and pharmacodynamics of amikacin and ceftazidime in tricuspid and aortic vegetations in experimental Pseudomonas endocarditis.

Authors:  A S Bayer; D J Crowell; J Yih; D W Bradley; D C Norman
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

8.  Pathogenic effects of monocytopenia, granulocytopenia and dexamethasone on the course of experimental Pseudomonas aeruginosa endocarditis in rabbits.

Authors:  A S Bayer; J Yih; C Y Chiu; C C Nast
Journal:  Chemotherapy       Date:  1989       Impact factor: 2.544

9.  Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus.

Authors:  K Sieradzki; A Tomasz
Journal:  J Bacteriol       Date:  1997-04       Impact factor: 3.490

10.  Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations.

Authors:  A S Bayer; K Lam
Journal:  J Infect Dis       Date:  1985-01       Impact factor: 5.226
View more
  11 in total

1.  Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis.

Authors:  Juliette Pavie; Agnès Lefort; Marie-Cécile Ploy; Laurent Massias; Françoise Chau; Louis Garry; François Denis; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 2.  Mechanisms of drug resistance: daptomycin resistance.

Authors:  Truc T Tran; Jose M Munita; Cesar A Arias
Journal:  Ann N Y Acad Sci       Date:  2015-10-23       Impact factor: 5.691

3.  Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  C F Dailey; C L Dileto-Fang; L V Buchanan; M P Oramas-Shirey; D H Batts; C W Ford; J K Gibson
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

4.  Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.

Authors:  J R Aeschlimann; G P Allen; E Hershberger; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

Review 5.  Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  Nelson Lee; Kwok-Yung Yuen; Cyrus R Kumana
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 6.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

7.  Combination of quinupristin-dalfopristin and gentamicin against methicillin-resistant Staphylococcus aureus: experimental rabbit endocarditis study.

Authors:  Eric Batard; Cedric Jacqueline; David Boutoille; Antoine Hamel; Henri B Drugeon; Nathalie Asseray; Roland Leclercq; Jocelyne Caillon; Gilles Potel; Denis Bugnon
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

Review 8.  Current Paradigms of Combination Therapy in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: Does it Work, Which Combination, and For Which Patients?

Authors:  Warren Rose; Michael Fantl; Matthew Geriak; Victor Nizet; George Sakoulas
Journal:  Clin Infect Dis       Date:  2021-12-16       Impact factor: 9.079

9.  Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.

Authors:  Aref Shariati; Masoud Dadashi; Majid Taati Moghadam; Alex van Belkum; Somayeh Yaslianifard; Davood Darban-Sarokhalil
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

10.  Differential Activity of the Combination of Vancomycin and Amikacin on Planktonic vs. Biofilm-Growing Staphylococcus aureus Bacteria in a Hollow Fiber Infection Model.

Authors:  Diane C Broussou; Marlène Z Lacroix; Pierre-Louis Toutain; Frédérique Woehrlé; Farid El Garch; Alain Bousquet-Melou; Aude A Ferran
Journal:  Front Microbiol       Date:  2018-03-27       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.